Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





NRTX-1001 for the Treatment of Drug-resistant Bilateral Temporal Lobe Focal Seizures

Neurology
Mona Sazgar
A Study of Inhibitory Interneurons (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Focal Seizures
Epilepsy

Study Description

This study is designed to obtain open-label feasibility, safety, and seizure frequency data in patients with drug-resistant bilateral mesial temporal lobe epilepsy (MTLE), with or without chronic indwelling intracranial electrodes. This is an open-label study of the bilateral administration of NRTX-1001, with the primary endpoint to evaluate safety and a secondary endpoint to evaluate seizure metrics during months 7-12 after NRTX-1001 administration. Up to ten subjects will receive 16x106 cells in each hippocampus.

Eligibility

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.